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M
onetary incentives to increase 
COVID-19 vaccinations are widely 
used. Do they work? Studies sug-
gest that payments were success-
fully used to increase vaccina-
tion for human papillomavirus in 
England (1), hepatitis B in the United States 
and United Kingdom (2), and tetanus tox-
oid in Nigeria (3). However, little is known 
about the effect of direct payment or lotter-
ies on COVID-19 vaccination rates. On page 
879 of this issue, a new study by Campos-
Mercade et al. (4) shows that monetary in-
centives changed behavior and increased 
vaccination in a large group. Yet ethicists 
hold a range of views about whether we 
should pay people to vaccinate.
Serbia was the first to adopt payments for 
COVID-19 vaccinations, announcing a $30 
reward (about 5% of the average monthly 
salary) in May 2021. That same month, vacci-
nated Hong Kongers became eligible to enter 
a lottery for a one-bedroom apartment worth 
$1.4 million and cash prizes totaling $12,890. 
In July 2021, US President Biden endorsed 
financial incentives, as did many US states.
Two studies in the United States suggested 
that using cash to increase COVID-19 vac-
cination rates might be effective (5, 6), but 
they relied on self-reports without actually 
paying people and observing effects. Another 
US study detected no significant associa-
tion between lottery announcements and 
vaccine uptake (7). Against this backdrop, 
Campos-Mercade et al. provide much needed 
insight. They report the results of a random-
ized controlled trial of unvaccinated people 
in Sweden (N = 8286) that paid people $24 if 
they vaccinated within 30 days. They found 
that vaccination increased 4.2%. No signifi-
cant group differences emerged based on age, 
education, race or ethnicity, or income. 
Yet questions remain. It is unclear 
whether participants who vaccinated would 
have done so eventually, without rewards, 
or whether paying more would increase vac-
cination or trigger suspicion and backfire. 
Research is needed to determine the study’s 
generalizability. Would $24 work in the 
United States, where 12% of the adult popu-
lation reported that they would get vacci-
nated only if required (8)? Would it change 
behavior in sub-Saharan Africa, where 60% 
of those who would reject the vaccine be-
lieve that it is less safe than other vaccines 
and nearly half think that COVID-19 was 
planned by foreign actors (9)?
WE CAN PAY, BUT SHOULD WE?
Even if it is possible to increase vaccination 
through cash payments, whether such pay-
ments are ethical is a contested issue. Several 
key issues arise in these debates.
Utility. Arguments defending monetary in-
centives often appeal to utilitarian principles, 
claiming that we should use whatever saves 
the most lives. For example, if education, 
encouragement, and facilitation fail, a pay-
ment-for-risk model is warranted (10). One 
counterargument is that narrowly focusing 
on saving lives may not be defensible given 
other urgent goals, like equity. Even if the 
sole end were saving lives, other means, such 
as mandates, may yield higher vaccination 
rates and save more lives.
Liberty. Another defense of monetary in-
centives puts a premium on minimizing in-
trusions into people’s lives and argues that 
monetary incentives are the least intrusive 
method to increase vaccination. One rebut-
tal is that other measures may work as well 
and restrict liberty less. For example, con-
versations with community leaders are less 
invasive and may work for undocumented 
immigrants who are concerned about depor-
tation or Catholics who are troubled by fetal 
cell lines used in vaccine development.
Civic responsibility. Another defense of 
monetary incentives maintains that they 
cultivate civic responsibility by rewarding 
good behavior. A counterargument is that 
monetary incentives encourage people to do 
things for money, not to be virtuous citizens. 
Historically, antivaccinators consistently in-
voked citizenship to defend their own view, 
interpreting “good citizenship” to mean hon-
oring diverse views and respecting the bodies 
of neighbors (11).
Equity. Arguments against cash incentives 
point to unequal effects on different seg-
ments of society (12). For example, a $100 
cash incentive may not feel coercive to 
prosperous people, yet it might to people 
who lost jobs during the pandemic. A re-
joinder is that it increases equality to pay 
people who are financially struggling. Yet 
such a one-time modest payment is unlikely 
to make a lasting difference in the lives of 
marginalized people. Another reply is that 
cash incentives increase equity by reducing 
infections in hard-hit groups. But this can 
be done without leveraging economic hard-
ship to increase vaccination.
Exploitation. Opponents of monetary incen-
tives argue that they might be exploitive, 
“taking advantage of [people] who have lost 
jobs, experienced food and housing insecu-
rity, or slipped into poverty” (13). Although 
some counter that cash inducements are 
not exploitive because they encourage a less 
risky choice (vaccination) (14), this misses the 
mark. What makes a transaction exploitive is 
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A woman receives a dose of Pfizer-BioNTech 
COVID-19 vaccine in Skåne County, Sweden. 































not its beneficial or harmful effects, but the 
nature of the transaction itself. Exploitive 
transactions use a person’s vulnerability to 
achieve someone else’s goals.
Autonomy. Other opponents argue that sub-
stituting cash for conversation insults the 
autonomy of vaccine refusers, signaling that 
their decisions can be bought. With lotteries, 
cash awards can manipulate decisions by le-
veraging cognitive biases, such as “probabil-
ity neglect,” which leads people to irrationally 
interpret probabilities in their favor (15). De-
fenders of monetary incentives might reply 
that it is paternalistic to assume that people 
offered cash cannot decide for themselves. 
Even if excessive payment or high-stakes lot-
teries unduly induce people to participate, 
modest cash awards do not. We also routinely 
pay people in other settings—for example, for 
research participation. In reply, safeguard-
ing autonomy calls for mitigating cognitive 
biases, not manipulating them. Even modest 
cash awards could unduly induce the least 
well-off to take part. The purpose of paying 
research subjects is compensating time and 
expenses, not inducing participation.
PROCEED WITH CAUTION
Policy-makers considering payment for vac-
cination should proceed with caution. Cash 
payments in Sweden may face fewer equity 
concerns than they do in low-income coun-
tries or for countries with meager safety nets 
and income inequality. In the United States, 
for example, cash incentives may be more ex-
ploitive and manipulative, and race-related 
differences in wealth could compound this ef-
fect for some minorities. Whether monetary 
incentives for vaccination are ethically sound 
or morally dubious may depend on the set-
ting to which they are applied. j
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from the lower mantle 
The calcium silicate compound was characterized 
and named as “davemaoite”
By Yingwei Fei
N
o one has ever successfully retrieved a 
high-pressure calcium silicate from the 




is “unquenchable,” meaning that it 
cannot retain its structure after be-
ing removed from its high-pressure environ-
ment. On page 891 of this issue, Tschauner et 
al. (1) report the first-ever silicate obtained 
from Earth’s lower mantle. They have coined 
the crystalline compound “davemaoite.” The 
sample is a CaSiO
3
-perovskite trapped inside 
of a diamond from the lower mantle. The au-
thors provide definitive evidence for a struc-
turally preserved cubic CaSiO
3
-perovskite by 
means of synchrotron x-ray diffraction.
The possibility that a high-pressure 
phase of CaSiO
3
 might exist in the lower 






solid solution (2). In 1975, scientists suc-
cessfully synthesized the CaSiO
3
- perovskite 
high-pressure phase with a cubic structure 
by using a laser-heated diamond anvil cell 
(3). Because of the unquenchable nature of 
the CaSiO
3
-perovskite phase, its structure 
has never been fully refined with single-
crystal x-ray diffraction, but powder x-ray 
diffraction data are broadly consistent with 
either a cubic perovskite structure (3, 4) 
or tetragonal symmetry, with very small 
differences between its long and short 
axis (5, 6). The natural sample obtained 
by Tschauner et al. shows an x-ray diffrac-




phase. Named after Dave Mao (also known 
as Ho-kwang Mao), an experimental geo-
physicist who contributed to high-pressure 
research over the past 50 years, davemao-
ite was approved as a new natural min-
eral by the Commission of New Minerals, 
Nomenclature, and Classification of the 
International Mineralogical Association.
Earth and Planets Laboratory, Carnegie Institution for 
Science, 5241 Broad Branch Road, NW, Washington DC 










INSIGHTS   |   PERSPECTIVES
Naming a newly  discovered 
high-pressure mineral
A mineral can only be given a proper name after its 
discovery  in nature. For minerals that exist only under high 
pressure, researchers  usually find them from one of two 
sources in nature: from Earth’s interior or inside meteorites. 
Davemaoite, a recently named calcium silicate crystal, 
was discovered inside a diamond in a mine in Botswana 
after ascending through Earth’s crust from more 
than 660 km underground.
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